synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
=== Co-franchising === By the mid-to late-1990s, Church's Chicken and hamburger chain White Castle announced their co-franchise, in which both companies would sell their own separate products, while operating in some shared restaurant spaces, with some shared personnel. In Canada, Church's Chicken items were once available in Harvey's restaurants, but the co-venture was discontinued.
HCO−3 is known as the bicarbonate ion. Calcium bicarbonate is many times more soluble in water than calcium carbonate—indeed it exists only in solution. Some of the HCO−3 combines with H+ in solution according to
=== Chronic cholecystitis === Chronic cholecystitis occurs after repeated episodes of acute cholecystitis and is almost always due to gallstones. Chronic cholecystitis may be asymptomatic, may present as a more severe case of acute cholecystitis, or may lead to a number of complications such as gangrene, perforation, or fistula formation. Xanthogranulomatous cholecystitis (XGC) is a rare form of chronic cholecystitis which mimics gallbladder cancer although it is not cancerous. It was first reported in the medical literature in 1976 by McCoy and colleagues.
Sources: en.wikipedia.org
== Legal status == Sweden's public health agency suggested classifying 4-fluorobutyrylfentanyl as hazardous substance on August 18, 2014. In October 2015, 4-fluorobutyrylfentanyl became a controlled substance in China. 4-Fluorobutyrfentanyl is a Schedule I controlled drug in the USA since 1. February 2018.
== Skin == Basal cell carcinoma Squamous cell carcinoma Squamous cell skin cancer Skin adnexal tumors (e.g. sebaceous carcinoma) Melanoma Merkel cell carcinoma Keratoacanthoma Sarcomas of primary cutaneous origin (e.g. dermatofibrosarcoma protuberans) Lymphomas of primary cutaneous origin (e.g. mycosis fungoides)
The reactions that produce, consume, and regenerate SAM are called the SAM cycle. In the first step of this cycle, the SAM-dependent methylases (EC 2.1.1) that use SAM as a substrate produce S-adenosyl homocysteine as a product. S-Adenosyl homocysteine is a strong negative regulator of nearly all SAM-dependent methylases despite their biological diversity. The S-adenosyl homocysteine is hydrolysed to homocysteine and adenosine by S-adenosylhomocysteine hydrolase and the homocysteine recycled back to methionine through transfer of a methyl group from 5-methyltetrahydrofolate, by one of the two classes of methionine synthases (i.e. cobalamin-dependent or cobalamin-independent). This methionine can then be converted back to SAM, completing the cycle. In the rate-limiting step of the SAM cycle, MTHFR (methylenetetrahydrofolate reductase) irreversibly reduces 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate.
On 3 January 2024, UNICEF chief Catherine M. Russell stated many children in Gaza were facing severe acute malnutrition. On 5 January, UNICEF found 90 percent of children under the age of two were eating two or fewer food groups a day. On 3 February, Hani Mahmoud, an Al Jazeera journalist in Rafah, stated, "We’re seeing children roaming around in Rafah looking for scraps of food." In early January 2024 UNICEF reported that around 90% of children in Gaza under 2 were subjected to severe food poverty, which had jumped from 80% about two weeks prior. Price jumps have also been seen by those attempting to purchase food, with a caregiver purchasing through a procurement company infant formula which had cost him $1,680 before the war, but paying $2,160 in February 2024. The United Nations stated on 10 February 2024 that 10 percent of children under five-years-old were suffering from acute malnourishment. One mother reported feeding her newborn using date paste. On 19 February 2024, UNICEF found that nearly 16 percent of children in northern Gaza under two-years-old were "acutely malnourished", with 3 percent suffering from severe wasting. In early March 2024 UNICEF reported that over 90% of children aged 6–23 months and pregnant or breastfeeding women face severe food poverty with access to two or fewer food groups a day. Child malnutrition is varied throughout Gaza, with northern Gaza experiencing worse food shortages then southern Gaza leading to a child malnutrition rate three times higher according to the WHO.
Sources: en.wikipedia.org
== Physical examination == The general appearance of patients may vary according to the experienced symptoms; the patient may be comfortable, or restless and in severe distress with an increased respiratory rate. A cool and pale skin is common and points to vasoconstriction. Some patients have low-grade fever (38–39 °C). Blood pressure may be elevated or decreased, and the pulse can become irregular. If heart failure ensues, elevated jugular venous pressure and hepatojugular reflux, or swelling of the legs due to peripheral edema may be found on inspection. Rarely, a cardiac bulge with a pace different from the pulse rhythm can be felt on precordial examination. Various abnormalities can be found on auscultation, such as a third and fourth heart sound, systolic murmurs, paradoxical splitting of the second heart sound, a pericardial friction rub and rales over the lung.
=== Infectious diseases === Imaging infections with molecular imaging technologies can improve diagnosis and treatment follow-up. Clinically, PET has been widely used to image bacterial infections using FDG to identify the infection-associated inflammatory response. Three different PET contrast agents have been developed to image bacterial infections in vivo are [18F]maltose, [18F]maltohexaose, and [18F]2-fluorodeoxysorbitol (FDS). FDS has the added benefit of being able to target only Enterobacteriaceae.
Because lichens accumulate pollutants over time, they allow for high-density spatial sampling, even in areas lacking automated monitoring stations. This makes X. parietina particularly useful for retrospective pollution assessments and long-term environmental monitoring. Findings from the Adriatic Italy study support its role as a reliable tool for tracking pollution trends, identifying pollutant sources, and informing environmental planning and public health strategies. Environmental influences on growth rate have important implications for biomonitoring studies that use X. parietina to assess air quality. Because the lichen accumulates pollutants over time, differences in growth rates between populations can affect pollutant load measurements. Thalli in humid, cooler environments may accumulate contaminants at a lower rate than those in drier, warmer habitats simply due to differences in growth and dilution effects. Consequently, lichen-based biomonitoring efforts must consider local climatic conditions to ensure accurate comparisons of atmospheric pollution levels across regions.
Cave 83 (Treasure Cave C) is part of the compact group of the four "Treasure Caves" (82, 83, 84, 85) located at the entrance of the central valley. It is a relatively small square cave (3.6x3.6m), with a podium in the middle, probably for a statue or a stupa. Here the ceiling has collapsed, but probably formed a cupola. The back wall had a well-preserved scene of a Jataka story, the Rudrayana Legend from the Divyavadana, with king Rudrayana observing the dance of his Queen Chandraprabha, who appears nude except for thin veils and jewelry. During the dance, the king had a premonition that his wife would soon die, and she asked to become a Buddhist nun. The style and attitudes of the figures are generally Indian, such as the Tribhanga posture of the dancer, of the way the King is seated. The flutering ribbons of the diadem worn by the king however, were adopted from Iranian royal symbolism. In this cave, the frames of the paintings, especially the vine rinceaux, are probably derived from Roman art of the 1st century CE. This cave may be slightly earlier then Cave 84. The mural was sent to Berlin by Grünwedel (Ref: MIK III 8443). These paintings are soft and delicate: volumes are defined by gradations of shades and colors, not by the sharp limit of a line. Overall, "the brush has the priority over drawing".
In 1972, French physicist Francis Perrin discovered fifteen ancient and no longer active natural nuclear fission reactors in three separate ore deposits at the Oklo mine in Gabon, Africa, collectively known as the Oklo Fossil Reactors. The ore deposit is 1.7 billion years old; then, uranium-235 constituted about 3% of uranium on Earth. This is high enough to permit a sustained chain reaction, if other supporting conditions exist. The capacity of the surrounding sediment to contain the health-threatening nuclear waste products has been cited by the U.S. federal government as supporting evidence for the feasibility to store spent nuclear fuel at the Yucca Mountain nuclear waste repository.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.